- $71.22m
- $12.76m
- $5.00m
- 19
- 15
- 39
- 13
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.33 | ||
| Price to Tang. Book | 1.34 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 14.24 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -121.18% | ||
| Return on Equity | n/a | ||
| Operating Margin | -1293.38% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 45.73 | n/a | 5 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Adlai Nortye Ltd. is a Cayman Islands-based investment holding company. The Company is involved in the research and development of pharmaceutical products. It is a clinical-stage company focused on the development of targeted and immune-modulating cancer therapies. It is advancing an oncology pipeline, with Buparlisib (AN2025), a pan-phosphoinositide 3-kinase (PI3K) inhibitor, being evaluated in a registrational Phase three trial (NCT04338399) for patients with recurrent or metastatic head and neck squamous cell cancer (HNSCC) that has progressed after prior anti-programmed death-ligand 1 (PD-L1) treatment. It is also advancing multiple drug candidates, including AN4005, an oral small molecule PD-L1 inhibitor; AN8025, a multifunctional fusion protein acting as a T cell and antigen-presenting cell (APC) modulator; and AN9025, an oral small molecule pan-rat sarcoma virus (RAS) inhibitor. The Company’s subsidiary, Alpine Bioscience Ltd. (Alpine BVI), is an investment holding company.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- May 19th, 2018
- Public Since
- September 29th, 2023
- No. of Employees
- 127
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 110,700,905
- Address
- c/o Ugland House, GRAND CAYMAN, KY1-1104
- Web
- https://www.adlainortye.com/
- Phone
- +1 8482307430
- Auditors
- Mazars USA LLP
Upcoming Events for ANL
Similar to ANL
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
What is the Adlai Nortye share price?
As of Today at 19:04 UTC, shares in Adlai Nortye are trading at $1.93. This share price information is delayed by 15 minutes.
How has the Adlai Nortye share price performed this year?
Shares in Adlai Nortye last closed at $1.93 and the price had moved by -85.18% over the past 365 days. In terms of relative price strength the Adlai Nortye share price has underperformed the S&P500 Index by -86.63% over the past year.
What are the analyst and broker recommendations for Adlai Nortye?
The overall consensus recommendation for Adlai Nortye is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Adlai Nortye dividend yield?
Adlai Nortye does not currently pay a dividend.
Does Adlai Nortye pay a dividend?
Adlai Nortye does not currently pay a dividend.
When does Adlai Nortye next pay dividends?
Adlai Nortye does not currently pay a dividend.
How do I buy Adlai Nortye shares?
To buy shares in Adlai Nortye you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Adlai Nortye?
As of the previous close price of $1.93, shares in Adlai Nortye had a market capitalisation of $71.22m.
Where are Adlai Nortye shares listed?
Here are the trading details for Adlai Nortye:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: ANL
What kind of share is Adlai Nortye?
Based on an overall assessment of its quality, value and momentum Adlai Nortye is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Adlai Nortye share price forecast for 2025?
The analyst consensus target price for shares in Adlai Nortye is $9.00. That is 366.32% above the last closing price of $1.93.
Analysts covering Adlai Nortye currently have a consensus Earnings Per Share (EPS) forecast of -$0.88 for the next financial year.
Find out moreWhat is the trend in the Adlai Nortye share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Adlai Nortye. Over the past six months, its share price has underperformed the S&P500 Index by -4.49%.
As of the last closing price of $1.93, shares in Adlai Nortye were trading -18.29% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Adlai Nortye PE Ratio?
The Adlai Nortye PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.93.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Adlai Nortye?
We do not have data on Adlai Nortye's directors